Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous AdenocarcinomaRecruitingPhase 22026-10-05NCT07504588

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Billings Clinic Cancer CenterBillingsUnited States272
Community Medical CenterMissoulaUnited States197
Highlands Oncology GroupSpringdaleUnited States62
Highlands Oncology Group - FayettevilleFayettevilleUnited States21
Highlands Oncology Group - RogersRogersUnited States30
Kootenai Clinic Cancer Services - Post FallsPost FallsUnited States223
Kootenai Clinic Cancer Services - SandpointSandpointUnited States169
Kootenai Health - Coeur d'AleneCoeur d'AleneUnited States209
Mercy Hospital SpringfieldSpringfieldUnited States240